Clinical trial
Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing
NCT07802626
Study timeline
Study start (estimated)2026-10-30Date precision: day
Registry last updated2026-09-03
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
HR Positive/HER-2 Negative Breast Cancerunresolved
Interventions
Sponsors & collaborators
SWOG Cancer Research Networklead sponsor
SWOG Clinical Trials Partnerships, LLCcollaborator
AstraZenecacollaborator
Guardant Health, Inc.collaborator
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07802626 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.